| Aug 28 |
Roth starts CG Oncology at buy, cites anticipated FDA filing
|
| Aug 26 |
CG Oncology: Promising Data, But Looks Expensive
|
| Aug 21 |
Bullish CG Oncology Insiders Loaded Up On US$5.06m Of Stock
|
| Aug 9 |
CG Oncology, Inc. reports Q2 results
|
| Aug 8 |
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
|
| Jul 25 |
Institutional investors in CG Oncology, Inc. (NASDAQ:CGON) must be dismayed after prices dropped by 13% last week
|
| Jul 21 |
Wall Street Breakfast: The Week Ahead
|
| Jul 9 |
CG Oncology Bringing Undervalued Innovation To Bladder Cancer
|
| Jun 18 |
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
|
| Jun 6 |
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
|
